Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcasts
Podcast Series Host
Your host for the Peer-to-Peer Podcast series is
Dr Laura Savage, Consultant Dermatologist from the Leeds Centre for Dermatology, Chapel Allerton Hospital and Honorary Senior Lecturer, University of Leeds, UK
Dr Laura Savage is a Consultant Dermatologist (Leeds Teaching Hospitals NHS Trust) with a special interest in Medical Dermatology and Honorary Senior Lecturer (Faculty of Medicine and Health, University of Leeds). She is co-lead for the complex psoriasis service and has extensive experience in utilising targeted immunomodulatory therapies.
Dr Savage graduated from the University of Edinburgh Medical School and subsequently trained in Dermatology within the Yorkshire Deanery. Her PhD focused on investigating the imaging and laboratory responses of subclinical disease within the synovio-entheseal complex in patients with moderate to severe psoriasis treated with biologic therapy. Her research interests cross the boundaries of both dermatology and rheumatology and relate to the development of strategies to detect and manage early PsA in patients with psoriasis. Dr Savage is also an active member of the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) and co-authored their published guidelines on the detection and treatment of enthesitis. As a natural continuation from her interest in biologic therapies, Dr Savage also has a keen interest in Hidradentiis Suppurativa. Dr Savage is an elected committee member of the British Society of Medical Dermatology. She takes an active role in medical education on a national and international level.
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
UK-RISN-220296 | Date of preparation: October 2022.